CYP2B6 and breast carcinoma: However, Ming et al. reported severe and prolonged hepatotoxicity in a breast cancer patient after two cycles of cyclophosphamide, which was attributed to the combined effect of the CYP2B6 variant with high cyclophosphamide 4-hydroxylation activity and the ALDH3A1 genetic variant with reduced detoxification activity78.